Additional Details
-
A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
GSK Investigational SiteLos Angeles CA. 90033 -
A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
GSK Investigational SiteHamilton L8N 4A6 -
A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
GSK Investigational SiteWilmington NC. 28401 -
A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
GSK Investigational SiteNewport Beach CA. 92663 -
A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
GSK Investigational SiteKissimmee FL. 34746 -
A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
GSK Investigational SitePhiladelphia PA. 19140 -
A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
GSK Investigational SiteTrois RiviEres G8T 7A1 -
A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
GSK Investigational SiteNew York NY. 10065 -
A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
GSK Investigational SiteAjax L1S 2J5 -
A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
GSK Investigational SiteAlbany NY. 12208 -
A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
GSK Investigational SiteJacksonville FL. 32224 -
A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
GSK Investigational SiteCypress CA. 77429 -
A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
GSK Investigational SiteNashville TN. 37204 -
A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
GSK Investigational SiteSaint John's A1B 3V6 -
A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
GSK Investigational SiteAnn Arbor MI. 48109-5360 -
A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
GSK Investigational SiteRochester NY. 55905 -
Collagen-targeted Positron Emission Tomography (PET) Imaging for Assessment of EGCG Effect
Massachusetts General HospitalBoston MA. 02114 -
Move With Air: Physiological Response Assessment
Centre of Innovative Medicine of the McGill University Health CentreMontreal QC. H4A 3J1 -
Move With Air: Exercise Training Study
Centre of Innovative Medicine of the McGill University Health CentreMontreal QC. H4A 3J1 -
A Follow-up Study to Test Long-term Treatment With BI 1015550 in People With Pulmonary Fibrosis Who Took Part in a Previous Study With BI 1015550
Dr. Georges-L.-Dumont University Hospital CentreMoncton NB. E1C 2Z3